Mater Today Bio. 2026 Nov 3;41:103806. doi: 10.1016/j.mtbio.2026.103806. eCollection 2026 Dec.
ABSTRACT
The defective hydrogen sulfide (H2S) metabolism in brain has emerged as a crucial pathogenic event and therapeutic target in Parkinson's disease (PD). However, current H2S delivery approaches for PD remain predominantly limited by the blood-brain barrier (BBB) and on-demand supply. This work aimed to upgrade the delivery of H2S to across BBB, thereby adequately harnessing its neuroprotective effect in PD brain. We developed a brain-penetrating, ROS-responsive H₂S nanocarrier (RVG29/TK@Lip/GYY) for targeted H₂S delivery in the PD brain. In this system, the H₂S donor GYY4137 was encapsulated within the liposomal core, and a ROS-responsive thioketal (TK) linker was incorporated into the lipid bilayer to enable on-demand H₂S release in the oxidative PD microenvironment. The liposomal surface was modified with the brain-homing peptide RVG29 to facilitate BBB crossing and neuronal targeting. This formulation achieved a good BBB penetration rate of 22.12%. In addition, pathological evaluation demonstrated that the controlled H2S release by RVG29/TK@Lip/GYY exerted multiple PD pathogenic interventions, including scavenging excessive ROS, alleviating nitrative stress, decreasing neuronal apoptosis, suppressing glial cell activation, and promoting nerve regeneration. Importantly, RVG29/TK@Lip/GYY treatment significantly attenuated the motor deficits of PD model mice. Collectively, this study not only provides a promising H2S nanocarrier for PD multiple pathological therapy, but also contributes to the development of H2S delivery in other neurodegenerative diseases treatment.
PMID:43034870 | PMC:PMC13769527 | DOI:10.1016/j.mtbio.2026.103806

